Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer

BJU International

Volumn 120, Issue 5, 2017, Pages E30-E44

  McDaniel, Andrew S ^a   Ferraldeschi, Roberta ^b,c   Krupa, Rachel ^d   Landers, Mark ^d   Graf, Ryon ^d   Louw, Jessica ^d   Jendrisak, Adam ^d   Bales, Natalee ^d   Marrinucci, Dena ^d   Zafeiriou, Zafeiris ^b,c   Flohr, Penelope ^b   Sideris, Spyridon ^b,c   Crespo, Mateus ^b   Figueiredo, Ines ^b   Mateo, Joaquin ^b,c   de Bono, Johann S ^b,c   Dittamore, Ryan ^d   Tomlins, Scott A ^a,e   Attard, Gerhardt ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Epic Sciences Inc   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

circulating tumour cells; ERG; liquid biopsy; metastatic castration resistant prostate cancer; PTEN

Indexed keywords

ANDROGEN RECEPTOR; CD45 ANTIGEN; CYTOKERATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL SIZE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ERG GENE; FETUS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; METASTASIS; MOLECULAR MODEL; ONCOGENE; OVERALL SURVIVAL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; BLOOD; DISEASE EXACERBATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHENOTYPE; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN;

EID: 84988410145     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13631     Document Type: Article

References (39)

1. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 2014; 11: 401–12
2. Diamond E, Lee GY, Akhtar NH et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2: 131
3. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61: 549–59
4. de Cremoux P, Extra JM, Denis MG et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 2000; 6: 3117–22
5. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129–44
6. Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 2013; 3: 377–94
7. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–91
8. Chen JF, Ho H, Lichterman J et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer 2015; 121: 3240–51
9. Armstrong AJ, Marengo MS, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997–1007
10. Larson CJ, Moreno JG, Pienta KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62: 46–53
11. Stott SL, Lee RJ, Nagrath S et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra3.
12. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912–8
13. Beltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res 2013; 19: 517–23
14. Brenner JC, Chinnaiyan AM, Tomlins SA. ETS fusion genes in prostate cancer. In Tindall DJ ed, Prostate Cancer: Biochemistry, Molecular Biology and Genetics, Vol. Protein Reviews. New York: Springer New York, 2013: 139–83.
15. Grasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–43
16. Hsieh HB, Marrinucci D, Bethel K et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893–9
17. Marrinucci D, Bethel K, Bruce RH et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007; 38: 514–9
18. Marrinucci D, Bethel K, Kolatkar A et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9: 016003
19. Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med 2009; 133: 1468–71
20. Werner SL, Graf RP, Landers M et al. Analytical Validation and Capabilities of the Epic CTC Platform: enrichment-Free Circulating Tumour Cell Detection and Characterization. J Circ Biomark 2015; 4: 3
21. Gundem G, Van Loo P, Kremeyer B et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520: 353–7
22. Crespo M, van Dalum G, Ferraldeschi R et al. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 2015; 112(Suppl): 1166–74
23. Carreira S, Romanel A, Goodall J et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6: 254ra125
24. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010; 2010: 617421
25. Pantel K, Deneve E, Nocca D et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem 2012; 58: 936–40
26. Reyal F, Valet F, de Cremoux P et al. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann Oncol 2011; 22: 1458–9
27. Ozkumur E, Shah AM, Ciciliano JC et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013; 5: 179ra47.
28. − CTCs. Cancer Discov 2011; 1: 580–6
29. Watanabe M, Uehara Y, Yamashita N et al. Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system. Cytometry A 2014; 85: 206–13
30. Giordano A, Gao H, Anfossi S et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012; 11: 2526–34
31. Yu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580–4.
32. Gorges TM, Tinhofer I, Drosch M et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012; 12: 178
33. Zhang L, Ridgway LD, Wetzel MD et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013; 5: 180ra48.
34. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–8
35. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22: 396–403
36. Ferraldeschi R, Nava Rodrigues D, Riisnaes R et al. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Eur Urol 2015; 67: 795–802
37. Udager AM, Shi Y, Tomlins SA et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate 2014; 74: 1199–208
38. Mehra R, Tomlins SA, Yu J et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584–90
39. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559–65